Each new oligonucleotide requires exhaustive safety testing—a process that is costly and time-consuming.
En el cruce entre la biología molecular y la ingeniería química, una nueva generación de medicamentos está desplazando el paradigma del tratamiento sintomático hacia la corrección de los errores moleculares que originan la enfermedad. Los oligonucleótidos terapéuticos —cadenas sintéticas que silencian mensajes genéticos defectuosos sin alterar el ADN— han pasado del laboratorio a la clínica con más de quince fármacos aprobados, y América Latina comienza a escribir su propio capítulo en esta historia: Argentina inauguró la primera planta regional dedicada a su fabricación. La pregunta que queda abierta no es si la tecnología funciona, sino si la humanidad puede construir la infraestructura necesaria para que llegue a quienes más la necesitan.
- Las enfermedades genéticas raras, antes condenadas al silencio terapéutico, ahora tienen un adversario molecular diseñado para neutralizar exactamente el error que las provoca.
- El principal obstáculo no es científico sino logístico: llevar estas moléculas a órganos de difícil acceso y sostener una fabricación costosa para condiciones que afectan a puñados de pacientes en todo el mundo.
- Argentina apostó 21,5 millones de dólares a convertirse en pionera regional, inaugurando en el Parque Industrial Pilar la primera planta latinoamericana de oligonucleótidos terapéuticos.
- La medicina de precisión ha comprimido el tiempo de desarrollo de años a meses, pero la complejidad regulatoria y la escala productiva siguen siendo muros que la velocidad científica aún no ha derribado.
Una nueva clase de medicamentos está cambiando la forma en que la medicina concibe la enfermedad. En lugar de aliviar síntomas, los oligonucleótidos terapéuticos intervienen en el origen molecular del problema: son cadenas cortas de nucleótidos sintéticos que localizan y silencian mensajes genéticos defectuosos, permitiendo que las células produzcan las proteínas correctas sin modificar de forma permanente el ADN del paciente. Adrian Krainer, genetista molecular del Cold Spring Harbor Laboratory, describe estas moléculas como más estables, menos tóxicas y con mejor distribución en el organismo que sus predecesoras. Su carga negativa y su tamaño inusual las distinguen de los fármacos convencionales y determinan cómo se mueven por los tejidos.
Desde que los primeros tratamientos basados en ARN llegaron al mercado a finales de la década de 2010, el campo no ha dejado de crecer. Hoy existen más de quince fármacos aprobados para enfermedades del hígado, el sistema nervioso central y los músculos, además de ciertos cánceres e infecciones virales. Sin embargo, la tecnología enfrenta un límite persistente: la entrega eficiente a órganos de difícil acceso. Cerebro, hígado y ojos responden bien; el resto del cuerpo sigue siendo una frontera abierta.
El proceso de fabricación exige una precisión química extraordinaria —cada nucleótido se añade uno a uno sobre un soporte sólido—, lo que garantiza fidelidad molecular pero encarece el desarrollo. Para enfermedades ultrarraras que afectan a pocos pacientes en el mundo, la ecuación económica se vuelve casi insostenible. La medicina de precisión ha acelerado los tiempos: analizando la secuencia genética individual de un paciente, hoy es posible diseñar y probar un oligonucleótido corrector en menos de un año, un ritmo impensable para el desarrollo farmacéutico tradicional.
En este contexto, Argentina dio un paso significativo. En 2026, el laboratorio Gador inauguró en el Parque Industrial Pilar la primera planta de América Latina dedicada exclusivamente a la producción de oligonucleótidos terapéuticos, con una inversión de 21,5 millones de dólares. La iniciativa posiciona al país como pionero regional en la fabricación de medicamentos de nueva generación y abre la posibilidad de desarrollar tratamientos adaptados a las necesidades genéticas de su propia población. Marisa Taverna, responsable del área en Gador, reconoce que escalar la producción y navegar la complejidad regulatoria siguen siendo desafíos formidables. La tecnología existe y funciona; el reto ahora es construir el mundo capaz de distribuirla.
A new class of medicines is rewriting how doctors think about disease. Instead of treating symptoms, these drugs target the molecular mistakes that cause illness in the first place—by working with RNA, the molecule that carries genetic instructions inside our cells, rather than altering DNA itself.
Therapeutic oligonucleotides are short chains of synthetic nucleotides, chemically engineered to seek out and block defective genetic messages. Think of them as precision editors: they find the corrupted instruction and silence it, allowing cells to produce the right proteins or preventing the wrong ones from being made. The approach sidesteps the permanence of genetic modification—the treatment works without rewriting the patient's fundamental blueprint. Adrian Krainer, a molecular geneticist at Cold Spring Harbor Laboratory in New York and a pioneer in this field, describes these molecules as more stable, less toxic, and better distributed throughout the body than their unmodified predecessors. They're also larger and carry a negative charge that conventional drugs don't, which changes how they move through tissue and how long they persist in the bloodstream.
The field moved from laboratory theory to clinical reality in the late 2010s, when the first RNA-based treatments reached the market. That breakthrough opened a floodgate. Today, more than fifteen oligonucleotide drugs have been approved to treat diseases of the liver, central nervous system, and muscles—genetic disorders, certain cancers, viral infections, and potentially widespread chronic conditions. Yet the technology remains constrained by a stubborn problem: getting these molecules to the right tissues. They work well in the brain, liver, and eyes. Reaching other organs remains an active frontier of research.
The manufacturing process itself is a feat of chemical precision. Each nucleotide is added one at a time, step by step, to a solid support, building the exact sequence needed for a particular disease. This controlled synthesis guarantees molecular fidelity. But because every new oligonucleotide sequence is unique, each one demands exhaustive safety testing—a process that is costly and time-consuming. For ultra-rare genetic diseases or highly specific mutations, the economics become brutal. Developing a treatment for a condition that affects only a handful of patients worldwide is technically possible but prohibitively expensive.
Precision medicine has accelerated this work. By analyzing a patient's individual genetic sequence and examining their RNA expression patterns, researchers can now identify the exact defect driving disease and design a corrective oligonucleotide in months. Krainer has seen it happen in under a year: synthesis, laboratory testing, safety evaluation in mice—all completed for patients carrying unique mutations. This speed is revolutionary compared to traditional drug development.
Argentina has emerged as a regional leader in bringing this technology to scale. In 2026, the pharmaceutical company Gador opened Latin America's first facility dedicated to manufacturing therapeutic oligonucleotides, a 21.5-million-dollar investment located in Pilar Industrial Park. The plant positions Argentina as a pioneer in producing next-generation medicines and enables the country to develop treatments tailored to its own population's genetic needs. Marisa Taverna, who oversees oligonucleotide development and production at Gador, frames the moment as a turning point: advances in genomics are pushing medicine toward treatments designed for individual patients, she said, though scaling production and managing regulatory complexity remain formidable challenges.
The broader challenge is clear. As more oligonucleotide therapies enter development, manufacturing capacity must expand to meet demand. Chemical modifications have solved many biological barriers, allowing drugs to penetrate cells and reach target tissues. But efficient delivery to difficult-to-access organs and the personalization of treatments for rare mutations still require breakthroughs. The technology works. The question now is whether the world can build the infrastructure to make it widely available.
Notable Quotes
ASOs are short chains of synthetic nucleic acid with chemical modifications that make them behave like drugs—more stable, less toxic, and better distributed throughout the body.— Adrian Krainer, molecular geneticist, Cold Spring Harbor Laboratory
Advances in genomics are pushing medicine toward treatments designed for individual patients, though scaling production and managing regulatory complexity remain formidable challenges.— Marisa Taverna, Gador oligonucleotide development and production manager
The Hearth Conversation Another angle on the story
Why does it matter that these drugs work through RNA instead of changing DNA itself?
Because it means the treatment is temporary and reversible. You're not rewriting the patient's genetic code permanently. You're correcting the message being sent, not the blueprint itself. Once the drug clears the body, the cells go back to their original state. That's a profound safety difference.
So a patient with a genetic disease could theoretically need repeated doses?
Possibly, yes. Some oligonucleotides have very long-lasting effects—months or even longer—but they're not permanent. For some conditions, that might mean periodic treatment. For others, it could mean a single dose that lasts years. We're still learning.
Why is manufacturing so difficult if the chemistry is understood?
Because every disease requires a different sequence. You can't mass-produce one oligonucleotide and use it for ten different conditions. Each new sequence needs its own safety testing, its own regulatory approval. That's expensive and slow, especially for rare diseases where there aren't many patients to justify the cost.
Argentina opening that factory—does that change the equation?
It's significant. It means Latin America isn't just importing these drugs anymore. They're building the capacity to design and manufacture treatments for their own populations. That's independence. It also means faster iteration and lower costs over time, as the facility scales up.
What's the biggest unsolved problem right now?
Getting these molecules to the right organs. They work beautifully in the liver and brain, but try reaching the pancreas or the heart, and you hit a wall. The chemistry is solved. The delivery is still the frontier.